Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

Abstract

UNLABELLED:

We evaluated the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). One hundred seven patients were enrolled. Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery (CRp) of 5%. The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies.

BACKGROUND:

The purpose of this study was to evaluate the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP).

PATIENTS AND METHODS:

One hundred seven patients with refractory/relapsed AML, intermediate and high-risk MDS, and CML-BP, with a performance status of 3 or less and normal organ function were treated. Patients received fludarabine 15 mg/m(2) intravenously (IV) every 12 hours on days 1 to 5 and cytarabine 0.5 g/m(2) IV over 2 hours every 12 hours on days 1 to 5. Gemtuzumab ozogamicin (GO) was administered at 3 mg/m(2) IV on day 1 in the first 59 patients. Patients with CML-BP were allowed to receive concomitant tyrosine kinase inhibitors.

RESULTS:

Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery of 5%. The overall 4-week mortality rate was 9%. The CR rates for patients with relapsed AML with first CR duration greater than or equal to 12 months, relapsed AML with first CR duration less than 12 months, and refractory/relapsed AML beyond first salvage were 56%, 26%, and 11%, respectively. With a median follow-up of 7 months, the 6-month event-free survival, overall survival, and complete remission CR duration rates were 18%, 35%, and 70%, respectively.

CONCLUSION:

BIDFA is active with an overall response rate of 26% in a heavily pretreated population. This combination is safe with a low 4-week mortality rate of 9%.

• Authors: Elias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, Farhad Ravandi, William Plunkett, Varsha Gandhi, Stefan Faderl, Susan O'Brien, Gautam Borthakur, Tapan Kadia, Jan Burger, Marina Konopleva, Mark Brandt, Xuelin Huang, Hagop Kantarjian
• Journal: Clinical lymphoma, myeloma & leukemia (Clin Lymphoma Myeloma Leuk) Vol. 12 Issue 4 Pg. 244-51 (Aug 2012) ISSN: 2152-2669 [Electronic] United States
• PMID: 22534616 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• Aminoglycosides
• Antibodies, Monoclonal, Humanized
• Cytarabine
• Gemtuzumab
• Vidarabine
• fludarabine

Topics

• Adult
• Aged
• Aged, 80 and over
• Aminoglycosides (administration & dosage, adverse effects)
• Antibodies, Monoclonal, Humanized (administration & dosage, adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Blast Crisis (pathology)
• Cytarabine (administration & dosage, adverse effects)
• Disease-Free Survival
• Gemtuzumab
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, pathology)
• Leukemia, Myeloid, Acute (drug therapy, pathology)
• Middle Aged
• Myelodysplastic Syndromes (drug therapy, pathology)
• Prognosis
• Recurrence
• Remission Induction
• Risk Factors
• Survival Analysis
• Vidarabine (administration & dosage, adverse effects, analogs & derivatives)
• Young Adult